AI-generated research brief — verify at source
SPP-004 Reduces Treatment Discontinuation in Leigh Syndrome Patients Who Responded to Initial Therapy
In a phase III randomized withdrawal trial, significantly fewer Leigh syndrome patients receiving SPP-004 discontinued treatment due to inadequate efficacy compared with those switched to placebo — 15.4% versus 50.0% at 48 weeks (p = 0.0486), with more than 80% of the SPP-004 group maintaining their clinical response. While the direction of findings is encouraging, the small double-blind sample size and wide confidence intervals require that these results be interpreted with caution.
What Was Studied
The trial investigated whether SPP-004 — a combination of 5-aminolevulinic acid hydrochloride and sodium ferrous citrate — could sustain clinical response in patients with Leigh syndrome who had already shown improvement during an initial open-label treatment phase. The primary endpoint was the proportion of patients who discontinued treatment due to inadequate efficacy over 48 weeks of double-blind follow-up, evaluated using the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS).
How It Was Studied
This was a phase III, double-blind, placebo-controlled, randomized withdrawal trial enrolling patients diagnosed with Leigh syndrome and presenting with central nervous system disorders. All 54 enrolled patients first underwent a 24-week open-label period during which everyone received SPP-004. Of these, 28 patients who demonstrated improvement on NPMDS subscales for cranial nervous and myopathy symptoms were eligible for the subsequent double-blind phase, where they were randomized 1:1 to continue SPP-004 (n = 14) or switch to placebo (n = 14) for 48 weeks. The full analysis set for the double-blind period comprised 13 patients in the SPP-004 group and 14 in the placebo group. Safety was assessed across all 54 patients who received SPP-004 at any stage.
What Was Observed
- Discontinuation due to inadequate efficacy was substantially lower in the SPP-004 group than in the placebo group — 15.4% versus 50.0% — a difference that reached statistical significance (95% CI for SPP-004: 1.9–45.4%; placebo: 23.0–77.0%; p = 0.0486). This means that roughly one in seven patients on SPP-004 failed to maintain response, compared to one in two on placebo.
- More than 80% of patients in the SPP-004 group maintained their clinical response through the 48-week double-blind period, indicating durable benefit among those who had initially responded to the drug during the open-label phase.
- All adverse drug reactions observed were classified as mild, and there were no meaningful differences in the overall adverse event profile between the SPP-004 and placebo groups across the study, suggesting an acceptable short-term tolerability profile at this stage of investigation.
Why This Matters
Leigh syndrome is a severe mitochondrial disease affecting the central nervous system, and effective maintenance therapies for the condition are extremely limited. This trial represents an attempt to generate phase III randomized controlled evidence for a potential treatment strategy in this rare pediatric population — a setting where rigorous trial data are scarce. The findings suggest that patients who achieve an initial clinical response to SPP-004 may sustain that benefit with continued treatment rather than relapsing when the drug is withdrawn.
How to Read This Result
Although the primary endpoint reached statistical significance, this is a small enriched-enrollment trial with wide confidence intervals and a medium quality signal, meaning the effect size estimate carries meaningful uncertainty and the result may not generalize to Leigh syndrome patients who do not respond to initial SPP-004 treatment.
Limitations
The double-blind phase enrolled only 28 patients (13–14 per group), substantially limiting statistical power and producing wide confidence intervals that reduce precision in estimating the true effect size. Crucially, only patients who responded during the open-label period were eligible for randomization — an enriched enrollment design that introduces selection bias and restricts generalizability to Leigh syndrome patients likely to benefit from SPP-004 at the outset. The rarity of the condition itself constrains recruitment and makes large-scale replication inherently difficult.